New Two-Drug combo could extend lives in advanced stomach cancer
NCT ID NCT06346197
Summary
This study is comparing a new two-drug immunotherapy combination (botensilimab + balstilimab) against standard chemotherapy plus immunotherapy for adults with advanced stomach or esophageal cancer that has specific genetic features. The main goal is to see if the new combination helps patients live longer. This is a Phase 3 trial, meaning it's a large, late-stage study designed to provide strong evidence about the treatment's effectiveness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de Poitiers
RECRUITINGPoitiers, 86000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centre Léon Bérard
RECRUITINGLyon, France
Contact Email: •••••@•••••
-
Hôpital Privé Jean Mermoz
RECRUITINGLyon, 69008, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut Paoli Calmettes
RECRUITINGMarseille, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.